Clinical Research Platform Into Molecular Testing, Treatment and Outcome of (Non-)Small Cell Lung Carcinoma Patients
Recruiting · NCT02622581 · Observational (researchers observe without assigning treatment) · Lead sponsor: AIO-Studien-gGmbH
View the official record on ClinicalTrials.gov →Interventions studied
data collection
What this trial is about
Open, non-interventional, prospective, multi-center clinical research platform with the main objective to assess molecular biomarker testing, treatment and outcome of patients with NSCLC or SCLC in Germany
Who can take part
Age range
18 Years and older
Sex
All (male and female)
Healthy volunteers
No - a diagnosis or condition is required
Phase
Not specified
Study type
Observational (researchers observe without assigning treatment)
Inclusion criteria
- Patients who meet all of the following criteria are eligible for the project:
- Age ≥ 18 years
- Able to understand and willing to sign written Informed Consent and to complete patient-reported-outcome assessment instruments
- Main project (Metatstatic NSCLC):
- Confirmed non-small cell lung cancer (NSCLC)
- Informed consent no later than four weeks after start of first-line systemic treatment or no later than four weeks after diagnosis for patients receiving "best supportive care only"
- Stage IV, or stage IIIB/C (UICC8) if patient is ineligible for curative surgery and/or radiochemotherapy
- Systemic therapy or best supportive care
- Satellite Stage I/II/III (NSCLC):
- Confirmed non-small cell lung cancer (NSCLC)
- Informed consent no later than four weeks after start of first anti-tumor treatment (including surgery and radiotherapy) or no later than four weeks after diagnosis for patients receiving "best supportive care only" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)
- Stage I, Stage II, stage IIIA, or stage IIIB/C (UICC8)
- Systemic (chemo)therapy and/or radiation therapy and/or surgery or best supportive care
- Satellite SCLC
- Confirmed Small cell lung cancer (SCLC)
- Informed consent no later than four weeks after start of first anti-tumor treatment or no later than four weeks after diagnosis for patients receiving "best supportive care only" (i.e. no anti-tumor treatment = no surgery, radiotherapy or systemic therapy)
- Systemic (chemo)therapy and/or radiation therapy and/or surgery or best supportive care
Exclusion criteria
- none
Where it is running
1 location listed.
- Pius-Hospital - Oldenburg, Germany